📈 Jumpstart Signal Watchlist — October 16, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $14.80 is 5% below 3yr high $15.60 · ⏳ SMA200 $7.81 (current price $14.80 is above) · 💰 Market Cap $835M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (13.3%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×1; showing 3 of 4).
✅ Paysign (NASDAQ:PAYS) Hits New 1-Year High — MarketBeat.
🤖 The article reports that Paysign reached a new one-year high and notes DA Davidson raised its price target to $15 while maintaining a Buy rating. The price-target increase and reported price momentum are positive signals.
✅ Paysign (NASDAQ:PAYS) Hits New 52-Week High — MarketBeat.
🤖 Paysign reached a new 52-week high, and the article notes DA Davidson raised its price objective to $15 with a Buy rating. These developments indicate positive analyst sentiment and recent share-price strength.
⚪️ Paysign CEO Mark Newcomer sells $766,895 of PAYS stock — Investing.com.
🤖 CEO Mark Newcomer sold 50,000 shares under a Rule 10b5-1 trading plan. The planned insider sale is a disclosed transaction, not by itself a clear directional catalyst for the stock.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $62.23 is 1% below 3yr high $62.83 · ⏳ SMA200 $49.74 (current price $62.23 is above) · 💰 Market Cap $15.5B
- EXEL shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Base breakout (range: 5.5%); Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×1 ⚪️×1).
✅ Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again — Zacks.
🤖 Zacks notes Exelixis has beaten earnings estimates in its last two reported quarters and has a positive Earnings ESP, suggesting potential for another earnings beat. This is a favorable near-term earnings signal, though it is not a report of new results.
⚪️ Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 — Business Wire.
🤖 This article only announces the date of Exelixis’s upcoming results and conference call, so it is excluded as a bare earnings-date announcement.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $64.00 is 8% below 3yr high $69.85 · ⏳ SMA200 $30.98 (current price $64.00 is above) · 💰 Market Cap $3.3B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (12.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1394% (>20%); Revenue growth 52% (>15%); ROE 26% (>15%).
⏰ Entry (E): 5/20
- 🔔 Strong above EMA50 (16.0%)
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (58) — BEARISH
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive (✅×3 ⚪️×2; showing 4 of 5).
✅ CareDx (CDNA) Stock Gets Fair Value Bump After ... — Yahoo Finance.
🤖 The article reports a modest increase in CareDx’s fair value estimate, citing favorable reimbursement developments and the Naveris acquisition. It also notes analyst optimism alongside valuation and execution concerns.
✅ BTIG raises CareDx stock price target to $74 on transplant outlook — Investing.com.
🤖 BTIG raised its price target from $60 to $74 and maintained a Buy rating, citing a favorable transplant outlook. The article also references CareDx’s strong second-quarter results and raised full-year outlook.
⚪️ CareDx (NASDAQ:CDNA) Shares Up 6% - Still a Buy? — MarketBeat.
🤖 The article notes a share-price rise and strong prior-quarter results, but also highlights that the average analyst price target is below the current share price and that analyst ratings are mixed. Its update date is October 17, 2026, so it is excluded from the requested publication window.
⚪️ CareDx (NASDAQ:CDNA) Hits New 1-Year High — MarketBeat.
🤖 The article reports a new one-year high and a Moderate Buy consensus, while noting the average price target is below the share price. The search result lists an October 5 publication date, but its October 16 update makes the original publication date unclear.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: Karat Packaging Inc. manufactures and distributes disposable foodservice products used by restaurants and other foodservice businesses. Its products include food and take-out containers, cups, lids, cutlery, straws, tableware, bags, and compostable packaging, along with related supplies and services.
- 🎯 Current $53.31 is 2% below 3yr high $54.68 · ⏳ SMA200 $34.09 (current price $53.31 is above) · 💰 Market Cap $1.1B
- KRT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (13.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 170% (>20%); ROE 30% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 5/20
- 🔔 VWMA trending up (5 consecutive days)
- ⚠️ RSI reversing from overbought (57) — BEARISH
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Full Transcript: Karat Packaging Q2 2026 Earnings Call - Karat Packaging (NASDAQ:KRT) — Benzinga.
🤖 The transcript covers the company’s second-quarter results, including adjusted EPS of $1.48, well above analyst expectations, supported by higher sales and a substantial tariff refund. Revenue was slightly below consensus, tempering the otherwise positive earnings news.
✅ Karat Packaging股价创历史新高，报$55.38 — Investing.com.
🤖 The article reports that KRT reached a record high, alongside strong year-to-date performance. It also notes the second-quarter adjusted EPS beat, though revenue came in slightly below analyst expectations.
✅ Specialty Equipment Distributors Stocks Q2 In Review: Karat Packaging (NASDAQ:KRT) Vs Peers — Yahoo Finance.
🤖 The review says Karat Packaging’s revenue grew 9.9% year over year and exceeded expectations, while EPS and EBITDA also beat estimates. It describes the quarter as strong.
🍭 Bonus (B): 0/10 — Rubber & Plastics Products

🏢 What they do: Best Buy Co., Inc. is a consumer electronics retailer that sells products such as computers, mobile phones, appliances, televisions, gaming equipment, and related accessories through its stores and online channels. It also provides technology services, including installation, repair, technical support, and product financing.
- 🎯 Current $92.63 is 10% below 3yr high $103.30 · ⏳ SMA200 $73.74 (current price $92.63 is above) · 💰 Market Cap $19.5B
- BBY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 70% (>20%); ROE 40% (>15%); Low LT D/E 0.37 (<1.0); Near-high ROE setup (52wk high + ROE).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Best Buy (NYSE:BBY) Stock Rating Upgraded by Wall Street Zen — MarketBeat.
🤖 Wall Street Zen upgraded Best Buy from Hold to Buy. The article also notes that the company’s reported quarterly EPS and revenue exceeded analyst expectations.
✅ Best Buy Ads expands reach with LG TV advertising partnership (BBY:NYSE) — Seeking Alpha.
🤖 Best Buy Ads partnered with LG Ad Solutions to give advertisers access to LG’s U.S. connected-TV inventory. The partnership could expand Best Buy’s advertising reach and create additional growth opportunities.
✅ Best Buy's Ads & Marketplace Expansion Opens New Growth Opportunities — Yahoo Finance.
🤖 The article describes growth in Best Buy’s Ads and Marketplace businesses, including a higher Marketplace forecast and raised fiscal 2027 operating-income-rate guidance. These developments point to stronger growth and margin contributions from the businesses.
🍭 Bonus (B): 0/10 — Radio, TV & Electronics Stores

🏢 What they do: Laureate Education, Inc. (LAUR) owns and operates a network of higher education institutions in Mexico, Peru, and the United States, offering undergraduate and graduate degree programs in business, medicine, health sciences, engineering, and information technology through campus-based, online, and hybrid formats.
- 🎯 Current $38.61 is 5% below 3yr high $40.46 · ⏳ SMA200 $35.40 (current price $38.61 is above) · 💰 Market Cap $5.3B
- LAUR passed all filters and shows favorable conditions.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (11.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 51% (>20%); Revenue growth 17% (>15%); ROE 28% (>15%).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 5/10
- 🗞️ News sentiment is neutral (mixed coverage; ✅×1 ❌×1 ⚪️×3; showing 4 of 5).
✅ Consumer Discretionary - Education Services Stocks Q2 Earnings Review — Yahoo Finance.
🤖 Laureate’s revenue rose 17.5% year over year and exceeded expectations, while full-year revenue guidance slightly topped analyst estimates. The article describes the quarter as satisfactory, though it says the results may already have been priced in.
❌ Laureate Education (NASDAQ:LAUR) Stock Price Expected to Rise? Morgan Stanley Analyst Says — MarketBeat.
🤖 Morgan Stanley raised its price target to $36.50 from $34.50 but maintained an underweight rating, indicating continued caution and a target below the share price reported in the article. The article also notes a Weiss Ratings upgrade, making the analyst signals mixed.
⚪️ Laureate Education surges 79% after Fair Value signal identified opportunity — Investing.com.
🤖 The article recounts a substantial past share-price gain and cites stronger enrollment, margins, and raised full-year guidance after Q2 results beat expectations. It also notes JPMorgan’s valuation-related downgrade, while the reported performance largely describes events already reflected in the stock.
⚪️ Laureate Education (NASDAQ:LAUR) Receives Consensus Rating of Hold from Analysts — MarketBeat.
🤖 Analyst recommendations were mixed, with four buys, two holds, and one sell, and an average price target of $40.50. The article also reports that quarterly EPS beat estimates, but the consensus rating itself is neutral.
🍭 Bonus (B): 0/10 — Educational Services